The risks associated with percutaneous native kidney biopsies: a prospective study.
kidney biopsy
logistic regression
major complications
prospective cohort study
risk
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
28 02 2023
28 02 2023
Historique:
received:
28
09
2021
pubmed:
20
5
2022
medline:
4
3
2023
entrez:
19
5
2022
Statut:
ppublish
Résumé
The known risks and benefits of native kidney biopsies are mainly based on the findings of retrospective studies. The aim of this multicentre prospective study was to evaluate the safety of percutaneous renal biopsies and quantify biopsy-related complication rates in Italy. The study examined the results of native kidney biopsies performed in 54 Italian nephrology centres between 2012 and 2020. The primary outcome was the rate of major complications 1 day after the procedure, or for longer if it was necessary to evaluate the evolution of a complication. Centre and patient risk predictors were analysed using multivariate logistic regression. Analysis of 5304 biopsies of patients with a median age of 53.2 years revealed 400 major complication events in 273 patients (5.1%): the most frequent was a ≥2 g/dL decrease in haemoglobin levels (2.2%), followed by macrohaematuria (1.2%), blood transfusion (1.1%), gross haematoma (0.9%), artero-venous fistula (0.7%), invasive intervention (0.5%), pain (0.5%), symptomatic hypotension (0.3%), a rapid increase in serum creatinine levels (0.1%) and death (0.02%). The risk factors for major complications were higher plasma creatinine levels [odds ratio (OR) 1.12 for each mg/dL increase, 95% confidence interval (95% CI) 1.08-1.17], liver disease (OR 2.27, 95% CI 1.21-4.25) and a higher number of needle passes (OR for each pass 1.22, 95% CI 1.07-1.39), whereas higher proteinuria levels (OR for each g/day increase 0.95, 95% CI 0.92-0.99) were protective. This is the first multicentre prospective study showing that percutaneous native kidney biopsies are associated with a 5% risk of a major post-biopsy complication. Predictors of increased risk include higher plasma creatinine levels, liver disease and a higher number of needle passes.
Sections du résumé
BACKGROUND
The known risks and benefits of native kidney biopsies are mainly based on the findings of retrospective studies. The aim of this multicentre prospective study was to evaluate the safety of percutaneous renal biopsies and quantify biopsy-related complication rates in Italy.
METHODS
The study examined the results of native kidney biopsies performed in 54 Italian nephrology centres between 2012 and 2020. The primary outcome was the rate of major complications 1 day after the procedure, or for longer if it was necessary to evaluate the evolution of a complication. Centre and patient risk predictors were analysed using multivariate logistic regression.
RESULTS
Analysis of 5304 biopsies of patients with a median age of 53.2 years revealed 400 major complication events in 273 patients (5.1%): the most frequent was a ≥2 g/dL decrease in haemoglobin levels (2.2%), followed by macrohaematuria (1.2%), blood transfusion (1.1%), gross haematoma (0.9%), artero-venous fistula (0.7%), invasive intervention (0.5%), pain (0.5%), symptomatic hypotension (0.3%), a rapid increase in serum creatinine levels (0.1%) and death (0.02%). The risk factors for major complications were higher plasma creatinine levels [odds ratio (OR) 1.12 for each mg/dL increase, 95% confidence interval (95% CI) 1.08-1.17], liver disease (OR 2.27, 95% CI 1.21-4.25) and a higher number of needle passes (OR for each pass 1.22, 95% CI 1.07-1.39), whereas higher proteinuria levels (OR for each g/day increase 0.95, 95% CI 0.92-0.99) were protective.
CONCLUSIONS
This is the first multicentre prospective study showing that percutaneous native kidney biopsies are associated with a 5% risk of a major post-biopsy complication. Predictors of increased risk include higher plasma creatinine levels, liver disease and a higher number of needle passes.
Identifiants
pubmed: 35587882
pii: 6589424
doi: 10.1093/ndt/gfac177
pmc: PMC9976765
doi:
Substances chimiques
Creatinine
AYI8EX34EU
Types de publication
Multicenter Study
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
655-663Informations de copyright
© The Author(s) 2022. Published by Oxford University Press on behalf of the ERA.
Références
Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1587-1594
pubmed: 33060158
Nephrol Dial Transplant. 1997 Mar;12(3):418-26
pubmed: 9075118
Clin J Am Soc Nephrol. 2020 Jul 1;15(7):1024-1026
pubmed: 32341009
Kidney Int Rep. 2020 Mar 04;5(4):511-518
pubmed: 32274455
Clin J Am Soc Nephrol. 2020 Nov 6;15(11):1595-1602
pubmed: 33060160
Eur J Clin Invest. 2007 Dec;37(12):954-63
pubmed: 18036029
Am J Nephrol. 2014;39(2):153-62
pubmed: 24526094
Nephron. 2020;144(1):14-20
pubmed: 31578024
Kidney Int. 2004 Sep;66(3):890-4
pubmed: 15327376
Nephrol Dial Transplant. 1998 Apr;13(4):975-7
pubmed: 9568860
Am J Kidney Dis. 1994 Apr;23(4):498-503
pubmed: 8154484
Clin Kidney J. 2018 Jun;11(3):330-336
pubmed: 29988286
Kidney Int. 2004 Oct;66(4):1570-7
pubmed: 15458453
Am J Kidney Dis. 1993 Oct;22(4):545-52
pubmed: 8213794
Kidney Int Rep. 2019 Jul 23;4(10):1435-1445
pubmed: 31701053
Nephrol Dial Transplant. 2011 May;26(5):1559-63
pubmed: 20858764
Am J Kidney Dis. 2012 Jul;60(1):62-73
pubmed: 22537423
Clin J Am Soc Nephrol. 2012 Oct;7(10):1591-7
pubmed: 22837269
BMJ Open. 2017 Jun 21;7(6):e015243
pubmed: 28637732
Curr Vasc Pharmacol. 2014 May;12(3):512-7
pubmed: 22724465